BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO

Core Insights - Bio-Techne Corporation has participated in Spear Bio's $45 million Series A funding round to accelerate product development and scale manufacturing capacity [1] - Spear Bio's ultra-sensitive detection technology offers significant advantages over traditional methods, enabling the quantification of low-abundance protein molecules, which is crucial for early diagnosis of neurodegenerative diseases [2][4] - The proprietary Successive Proximity Extension Amplification Reaction (SPEAR) technology allows for measuring protein biomarkers at attomolar levels from sub-microliter sample volumes, significantly reducing background noise compared to conventional assays [4][6] Company Overview - Bio-Techne Corporation is a global life sciences company that generated over $1.1 billion in net sales in fiscal 2023 and employs approximately 3,100 people worldwide [5] - Spear Bio, founded in 2021, focuses on developing ultra-sensitive immunoassays and is headquartered in Woburn, Massachusetts [4][6] - The collaboration between Bio-Techne and Spear Bio highlights the potential of SPEAR technology to transform protein research and early disease diagnosis [5]